FOLD Quote, Financials, Valuation and Earnings

Alnylam Pharmaceuticals has a net margin of -17.31% compared to Amicus Therapeutics's net margin of -9.67%. Amicus Therapeutics's return on equity of -17.7% beat Alnylam Pharmaceuticals's return on equity of --.

Amicus Therapeutics has a consensus price target of $15.82, signalling upside risk potential of 160.6%. On the other hand Alnylam Pharmaceuticals has an analysts' consensus of $330.77 which suggests that it could grow by 2.47%. Given that Amicus Therapeutics has higher upside potential than Alnylam Pharmaceuticals, analysts believe Amicus Therapeutics is more attractive than Alnylam Pharmaceuticals.

Amicus Therapeutics has a beta of 0.508, which suggesting that the stock is 49.181% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals has a beta of 0.226, suggesting its less volatile than the S&P 500 by 77.386%.

Amicus Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amicus Therapeutics pays -- of its earnings as a dividend. Alnylam Pharmaceuticals pays out -- of its earnings as a dividend.

Amicus Therapeutics quarterly revenues are $125.2M, which are smaller than Alnylam Pharmaceuticals quarterly revenues of $594.2M. Amicus Therapeutics's net income of -$21.7M is higher than Alnylam Pharmaceuticals's net income of -$57.5M. Notably, Amicus Therapeutics's price-to-earnings ratio is -- while Alnylam Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amicus Therapeutics is 3.42x versus 17.67x for Alnylam Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Blueprint Medicines has a net margin of -17.31% compared to Amicus Therapeutics's net margin of 0.33%. Amicus Therapeutics's return on equity of -17.7% beat Blueprint Medicines's return on equity of -49.13%.

Amicus Therapeutics has a consensus price target of $15.82, signalling upside risk potential of 160.6%. On the other hand Blueprint Medicines has an analysts' consensus of $126.87 which suggests that it could fall by -1.87%. Given that Amicus Therapeutics has higher upside potential than Blueprint Medicines, analysts believe Amicus Therapeutics is more attractive than Blueprint Medicines.

Amicus Therapeutics has a beta of 0.508, which suggesting that the stock is 49.181% less volatile than S&P 500. In comparison Blueprint Medicines has a beta of 0.894, suggesting its less volatile than the S&P 500 by 10.564%.

Amicus Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Blueprint Medicines offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amicus Therapeutics pays -- of its earnings as a dividend. Blueprint Medicines pays out -- of its earnings as a dividend.

Amicus Therapeutics quarterly revenues are $125.2M, which are smaller than Blueprint Medicines quarterly revenues of $149.4M. Amicus Therapeutics's net income of -$21.7M is lower than Blueprint Medicines's net income of $496K. Notably, Amicus Therapeutics's price-to-earnings ratio is -- while Blueprint Medicines's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amicus Therapeutics is 3.42x versus 14.74x for Blueprint Medicines. Usually stocks with elevated PS ratios are considered overvalued.

Sarepta Therapeutics has a net margin of -17.31% compared to Amicus Therapeutics's net margin of -60.08%. Amicus Therapeutics's return on equity of -17.7% beat Sarepta Therapeutics's return on equity of -20.94%.

Amicus Therapeutics has a consensus price target of $15.82, signalling upside risk potential of 160.6%. On the other hand Sarepta Therapeutics has an analysts' consensus of $44.54 which suggests that it could grow by 144.39%. Given that Amicus Therapeutics has higher upside potential than Sarepta Therapeutics, analysts believe Amicus Therapeutics is more attractive than Sarepta Therapeutics.

Amicus Therapeutics has a beta of 0.508, which suggesting that the stock is 49.181% less volatile than S&P 500. In comparison Sarepta Therapeutics has a beta of 0.448, suggesting its less volatile than the S&P 500 by 55.179%.

Amicus Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amicus Therapeutics pays -- of its earnings as a dividend. Sarepta Therapeutics pays out -- of its earnings as a dividend.

Amicus Therapeutics quarterly revenues are $125.2M, which are smaller than Sarepta Therapeutics quarterly revenues of $744.9M. Amicus Therapeutics's net income of -$21.7M is higher than Sarepta Therapeutics's net income of -$447.5M. Notably, Amicus Therapeutics's price-to-earnings ratio is -- while Sarepta Therapeutics's PE ratio is 20.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amicus Therapeutics is 3.42x versus 0.91x for Sarepta Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

TG Therapeutics has a net margin of -17.31% compared to Amicus Therapeutics's net margin of 4.19%. Amicus Therapeutics's return on equity of -17.7% beat TG Therapeutics's return on equity of 19.78%.

Amicus Therapeutics has a consensus price target of $15.82, signalling upside risk potential of 160.6%. On the other hand TG Therapeutics has an analysts' consensus of $40.50 which suggests that it could grow by 4.27%. Given that Amicus Therapeutics has higher upside potential than TG Therapeutics, analysts believe Amicus Therapeutics is more attractive than TG Therapeutics.

Amicus Therapeutics has a beta of 0.508, which suggesting that the stock is 49.181% less volatile than S&P 500. In comparison TG Therapeutics has a beta of 1.913, suggesting its more volatile than the S&P 500 by 91.257%.

Amicus Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TG Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amicus Therapeutics pays -- of its earnings as a dividend. TG Therapeutics pays out -- of its earnings as a dividend.

Amicus Therapeutics quarterly revenues are $125.2M, which are larger than TG Therapeutics quarterly revenues of $120.9M. Amicus Therapeutics's net income of -$21.7M is lower than TG Therapeutics's net income of $5.1M. Notably, Amicus Therapeutics's price-to-earnings ratio is -- while TG Therapeutics's PE ratio is 161.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amicus Therapeutics is 3.42x versus 16.16x for TG Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.